Investor Relations

Investor Relations

Ampio Pharmaceuticals Inc. Tel: 1-720-437-6500
Please use this form to request an investor information pack about Ampio Pharmaceuticals, Inc.

Click here for our stock information

 








Name:
*
Company:
Address 1:
*
Address 2:
City:
*
Country:
*
State:
Province:
Zip or Postal Code:
*
Phone:
*
Fax:
Email:
*
Best time to call:
*
Message:
*
Fields, marked with * are required.

Learn More About:

Premature Ejaculation (PE)

Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction (ED) and has a major impact on the quality of life for men and their sexual partners.

Diabetic Retinopathy

A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness

Diabetic Nephropathy

A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis

AMPE Stock Quote - delayed
Last Change
AMPE 2.67 Down 0.14 (4.98%)

Ampio News

05/14/2012 | Press Release

Ampio Pharmaceuticals Schedules 2012 Update Webcast

05/11/2012 | Press Release

Ampio Pharmaceuticals Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion™ for the Treatment of Chronic Pain of Osteoarthritis of the Knee and Schedules May 16th Webcast to Update Shareholders

04/30/2012 | Press Release

Ampio Pharmaceuticals announces extended analysis of Ampion™ In the Knee (AIK) Study shows pain relief of osteoarthritis, 84 days after a single injection into the knee, is statistically significant

» See all Ampio news